オプションチェーンは、Palatin Techsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Palatin Techsの市場センチメントを評価します。.

Palatin Techs (AMEX:PTN) 株価情報, オプションチェーン

Palatin Techs

Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.

Palatin Technologies Inc

PT Bank CIMB Niaga Tbk

PT VALE INDONESIA TBK by PT Vale Indonesia TBK

PT Vale Indonesia Tbk

PT VALE INDONESA UNSP/ADR by PT Vale Indonesia TBK

PT INDO KORDSA TBK by PT INDO KORDSA TBK

Pacer Trendpilot 100 ETF

PARTNER COMMUNS CO ORD by Partner Communications Company Ltd.

Partner Communications Co Ltd

Partner Communications Co Ltd ADR

PLATINA RESOURCES LTD ORD by Platina Resources, Ltd.

Platina Resources Ltd

ParcelPal Logistics Inc

PARCELPAL LOGISTICS INC by PARCELPAL LOGISTICS INC.

<ul>
<li>Co-administered bremelanotide + tirzepatide, bremelanotide alone, and tirzepatide alone arms showed improvement in appetite suppression, fullness, and satiety</li>
<li>Bremelanotide matched or exceeded tirzepatide in appetite suppression</li>
<li>Low-dose bremelanotide helped prevent appetite rebound after tirzepatide cessation</li>
</ul>
CRANBURY, N.J., April 17, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PTN#NYSE">PTN</a>), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced positive appetite suppression results from its BMT-801 Phase 2 obesity study. The study included a co-administered melanocortin 4 receptor (MC4R) agonist bremelanotide plus glucagon like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) tirzepatide arm, bremelanotide alone, and tirzepatide alone arms.
Key Results – Appetite Suppression (Patient-Reported Outcomes)
Using a validated daily appetite questionnaire, the study showed that patients receiving co-administered bremelanotide + tirzepatide, tirzepatide alone, and bremelanotide alone, experienced&nbsp; significant improvements in appetite suppression, fullness, and satiety. Patients who transitioned to placebo after initial weight loss on tirzepatide showed no improvement for appetite suppression.
<ul>
<li>Overall appetite suppression
<ul>
<li>Bremelanotide + tirzepatide: 71% increase</li>
<li>Tirzepatide only: 73% increase</li>
<li>Bremelanotide only: 71% increase</li>
</ul>
</li>
<li>"How full do you feel (fullness)?"
<ul>
<li>Bremelanotide + tirzepatide: 65% increase</li>
<li>Tirzepatide only: 62% increase</li>
<li>Bremelanotide only: 79% increase</li>
</ul>
</li>
<li>"How satisfied do you feel (satiety)?"
<ul>
<li>Bremelanotide + tirzepatide: 56% increase</li>
<li>Tirzepatide only: 56% increase</li>
<li>Bremelanotide only: 68% increase</li>
</ul>
</li>
</ul>
Consistent with known effects of GLP-1/GIP therapy, over 50% of lost weight was regained within two weeks of stopping treatment in both the tirzepatide and co-administration arms of the study. In contrast, patients who transitioned to low-dose bremelanotide after initial weight loss on tirzepatide maintained their weight without any significant regain,&nbsp;underscoring the potential of MC4R agonists as a valuable therapy for long-term weight maintenance.&nbsp;
Topline results from the BMT-801 Phase 2 trial, released last month, demonstrated statistically significant weight loss with bremelanotide co-administered with tirzepatide versus placebo over an 8-week treatment period. Further analysis of secondary and exploratory endpoints—including body composition and BMI—is ongoing. &nbsp;

News

Palatin Technologies Announces Positive Appetite Suppression Results From BMT-801 Phase 2 Obesity Study

<h3>Gainers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock increased by 76.0% to $0.04 during Monday's pre-market session. </li>
<li>Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) shares increased by 37.36% to $5.0. The company's market cap stands at $225.5 million. </li>
<li>Verve Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) shares increased by 32.2% to $4.31. The company's market cap stands at $382.7 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares moved upwards by 27.6% to $0.16. The market value of their outstanding shares is at $4.7 million. </li>
<li>Artelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) shares rose 26.52% to $1.04. The market value of their outstanding shares is at $3.3 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock increased by 22.3% to $0.2. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Gyre Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>) shares declined by 17.4% to $6.21 during Monday's pre-market session. The company's market cap stands at $581.3 million. </li>
<li>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) stock fell 16.45% to $0.79. The market value of their outstanding shares is at $126.4 million. </li>
<li>Virax Biolabs Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) shares declined by 14.18% to $0.95. The company's market cap stands at $4.1 million. </li>
<li>Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) shares decreased by 12.67% to $1.24. The company's market cap stands at $3.3 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock declined by 11.7% to $0.26. The company's market cap stands at $1.9 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) stock declined by 11.61% to $2.21. The company's market cap stands at $4.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ARTL

GYRE

IRWD

KTTA

MSPR

PTIX

STSS

THRD

VERV

VRAX

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Monday's Pre-Market Session

Palatin Technologies, Inc. (the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PTN#NYSE">PTN</a>), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced today that it has formally appealed the NYSE Regulation determination to&nbsp;delist its common stock.
&nbsp;
NYSE Regulation determined the Company was unable to demonstrate that it had regained compliance with Sections 1003(a)(i), (ii) and (iii), related to stockholders' equity requirements, by the end of the maximum 18-month compliance plan period, which expired on April 10, 2025.
Palatin's common stock will continue to trade on the NYSE American during the appeal process, which is expected to last 60-to-90-days. A final decision from the NYSE Listings Qualifications Panel will determine whether the stock remains listed or is delisted.
Palatin is actively implementing a plan to strengthen its financial position and regain compliance, including:
<ul>
<li>Accelerating out-licensing discussions across key development programs</li>
<li>Advancing equity financing negotiations</li>
<li>Exploring strategic funding opportunities</li>
</ul>
"We are moving quickly and deliberately to address the listing requirements," said Carl Spana, Ph.D., President and Chief Executive Officer of Palatin. "We believe the actions underway can restore compliance and create a stronger foundation for growth."
There can be no assurance the appeal will be successful. However, the Company is optimistic it will meet the listing requirement and remains committed to delivering value for its shareholders. &nbsp;

Government

Regulations

Palatin Technologies Appeals NYSE Delisting Decision, Seeks to Regain Compliance in 90 Days

<h3>Gainers</h3>
<ul>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares rose 86.6% to $9.52 during Friday's regular session. The market value of their outstanding shares is at $15.6 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) stock moved upwards by 85.15% to $2.37. The company's market cap stands at $5.0 million. </li>
<li>CeriBell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBLL#NASDAQ">CBLL</a>) shares rose 35.78% to $15.14. The company's market cap stands at $543.0 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares increased by 35.02% to $38.13. The company's market cap stands at $496.1 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares moved upwards by 34.42% to $0.02. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) shares rose 27.88% to $0.27. The company's market cap stands at $22.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) stock fell 53.3% to $2.31 during Friday's regular session. The company's market cap stands at $5.6 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock declined by 44.04% to $0.24. The market value of their outstanding shares is at $6.1 million. </li>
<li>Wellgistics Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGRX#NASDAQ">WGRX</a>) shares declined by 29.45% to $2.76. The market value of their outstanding shares is at $143.2 million. </li>
<li>Organovo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) stock fell 22.96% to $1.68. The market value of their outstanding shares is at $3.0 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock declined by 21.52% to $0.22. The company's market cap stands at $1.3 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares declined by 15.96% to $0.48. The market value of their outstanding shares is at $5.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CBLL

LUCY

ONVO

PRTG

RSLS

WGRX

YCBD

12 Health Care Stocks Moving In Friday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) shares increased by 124.2% to $2.87 during Friday's pre-market session. The company's market cap stands at $6.0 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock increased by 31.69% to $0.02. </li>
<li>Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) shares moved upwards by 22.17% to $31.45. The company's market cap stands at $632.4 million. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) stock rose 20.43% to $7.77. The company's market cap stands at $5.8 million. </li>
<li>Certara (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) stock moved upwards by 18.36% to $12.44. The market value of their outstanding shares is at $2.0 billion. </li>
<li>Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) stock moved upwards by 17.74% to $2.19. The market value of their outstanding shares is at $162.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Performant Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHLT#NASDAQ">PHLT</a>) shares declined by 38.0% to $1.5 during Friday's pre-market session. The company's market cap stands at $117.4 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock decreased by 35.26% to $0.18. The market value of their outstanding shares is at $1.1 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock decreased by 31.64% to $0.29. The company's market cap stands at $7.5 million. </li>
<li>KORU Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRMD#NASDAQ">KRMD</a>) shares fell 29.39% to $1.61. The market value of their outstanding shares is at $74.2 million. </li>
<li>Organovo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) stock declined by 24.78% to $1.64. The market value of their outstanding shares is at $2.9 million. </li>
<li>Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) stock declined by 23.08% to $8.0. The market value of their outstanding shares is at $1.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CATX

CERT

KRMD

MESO

NAOV

PHLT

12 Health Care Stocks Moving In Friday's Pre-Market Session

Shares of argenx SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) rose sharply in today's pre-market trading after the company announced the FDA approval of VYVGART Hytrulo prefilled syringe for self-injection in generalized myasthenia gravis and <a href="https://www.benzinga.com/quote/ARGX">chronic inflammatory demyelinating polyneuropathy.</a>
argenx shares jumped 5.1% to $573.88 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>MSP Recovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) rose 167% to $3.43 in pre-market trading as the company announced strategic term sheet providing prospective liquidity and restructuring of existing agreements to remove corporate guaranteed debt by over $1.2 billion as well as new agreements aimed at driving future growth.</li>
<li>Sharps Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) surged 73.6% to $0.0318 in pre-market trading after jumping 30% on Thursday.</li>
<li>Enzo Biochem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) gained 26.5% to $0.3300 in pre-market after dipping 22% on Thursday.</li>
<li>Actelis Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASNS#NASDAQ">ASNS</a>) rose 26.4% to $0.8198 in pre-market trading. Actelis Networks recently announced it received a new order to modernize Orange County&#8217;s traffic infrastructure.</li>
<li>Venus Concept Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) rose 25.6% to $5.10 in pre-market trading. Venus Concept announced closing of $1.1 million registered direct offering of common stock priced at-the-market under Nasdaq rules.</li>
<li>DMC Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOOM#NASDAQ">BOOM</a>) gained 21.7% to $7.90 in pre-market trading.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) jumped 19.1% to $5.37 in pre-market trading.</li>
<li>Certara, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) surged 18.1% to $12.41 in pre-market trading after gaining 8% on Thursday.</li>
<li>Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) gained 13.7% to $29.23 in pre-market trading. The stock may be moving up after the FDA stated plans to phase out animal testing requirements for monoclonal antibodies and other drugs.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>AlTi Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTI#NASDAQ">ALTI</a>) fell 57.3% to $1.20 in pre-market trading after declining around 6% on Thursday.</li>
<li>cbdMD, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#NYSE">YCBD</a>) shares tumbled 38.9% to $0.1701 in pre-market trading. CbdMD announced shareholder approval of automatic conversion of series a preferred stock and other results from annual meeting.</li>
<li>Nexa Resources S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEXA#NYSE">NEXA</a>) fell 32% to $4.01 in today's pre-market trading.</li>
<li>Organovo Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) shares fell 27.1% to $1.59 in pre-market trading.</li>
<li>Palatin Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PTN#NYSE">PTN</a>) fell 16.8% to $0.3510 in pre-market trading after the company announced it received a NYSE American notice of delisting.</li>
<li>Betterware de México, S.A.P.I. de C.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWMX#NYSE">BWMX</a>) shares fell 24% to $8.21 in pre-market trading. Betterware de México will report its first quarter results after the U.S. market close on Thursday, April 24.</li>
<li>Solaris Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLSR#NYSE">SLSR</a>) shares dipped 22.3% to $2.20 in pre-market trading.</li>
<li>InnovAge Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) fell 14.9% to $2.35 in pre-market trading.</li>
<li>Costamare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMRE#NYSE">CMRE</a>) dipped 14.3% to $7.42 in pre-market trading after falling 5% on Thursday.</li>
<li>Maze Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) declined 12.8% to $6.62 in pre-market trading after falling 5% on Thursday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44734419/top-2-real-estate-stocks-that-may-keep-you-up-at-night-this-month">Top 2 Real Estate Stocks That May Keep You Up At Night This Month</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

ALTI

ARGX

ASNS

BOOM

BWMX

CMRE

INNV

MAZE

NEXA

RXRX

SLSR

VERO

Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares moved upwards by 36.7% to $5.55 during Thursday's after-market session. The company's market cap stands at $3.6 million. </li>
<li>Creative Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) shares moved upwards by 31.03% to $2.36. The company's market cap stands at $5.9 million. </li>
<li>Organovo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) shares rose 30.27% to $2.84. The company's market cap stands at $5.1 million. </li>
<li>Certara (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) stock moved upwards by 26.67% to $13.44. The company's market cap stands at $2.1 billion. </li>
<li>Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) stock moved upwards by 24.7% to $32.1. The company's market cap stands at $645.5 million. </li>
<li>Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) stock rose 20.61% to $5.44. The company's market cap stands at $2.1 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) stock fell 27.0% to $1.03 during Thursday's after-market session. The company's market cap stands at $34.7 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) shares fell 26.34% to $0.31. The company's market cap stands at $8.0 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) stock fell 13.77% to $4.29. The market value of their outstanding shares is at $10.5 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares fell 13.29% to $0.38. The market value of their outstanding shares is at $2.0 million. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares declined by 10.86% to $5.75. The market value of their outstanding shares is at $4.3 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares declined by 9.72% to $0.25. The market value of their outstanding shares is at $1.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CELZ

NIVF

NOTV

12 Health Care Stocks Moving In Thursday's After-Market Session

WIIM

Palatin Technologies shares are trading lower after the company announced it received a NYSE American notice of delisting.

General

Palatin Technologies Receives NYSE American Notice Of Delisting And Intention To Appeal

<ul>
<li>Six-month open-label study showed clinically meaningful improvements in kidney function and disease in patients with Type 2 diabetic nephropathy.
<ul>
<li>71% achieved a &gt;30% reduction in UP/Cr, a key indicator of kidney damage.</li>
<li>71% demonstrated improved or stabilized&nbsp;eGFR,&nbsp;signaling&nbsp;preserved kidney function.</li>
<li>37.5% had increased urinary&nbsp;VEGF levels,&nbsp;suggesting better blood vessel support in the kidneys.</li>
<li>36% had reduced urinary&nbsp;synaptopodin losses,&nbsp;indicating healthier kidney cells and structure.</li>
</ul>
</li>
</ul>

Palatin Technologies Reports 71% Of Patients Achieved >30% UP/Cr Reduction In Phase 2b Diabetic Kidney Study

Palatin Technologies Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PTN#NYSE">PTN</a>) on Monday reported topline data with co-administered melanocortin-4 receptor (MC4R) agonist bremelanotide plus glucagon-like peptide-1/gastric inhibitory polypeptide <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">(GLP-1/GIP) tirzepatide</a>.
Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) tirzepatide is available as Mounjaro and Zepbound for diabetes and weight loss.
Topline data results from the study were highly statistically significant for the study&#8217;s primary endpoint, which was percent weight loss in patients for the co-administration of MC4R agonist bremelanotide plus&nbsp;GLP-1/GLP tirzepatide compared to placebo, over the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44558732/palatin-announces-mc4r-agonist-bremelanotide-co-administered-with-glp-1gip-tirzepatide-meets-prima" rel="noreferrer noopener">8-week treatment period</a>.
<ul>
<li>The co-administered group had a 4.4% reduction in weight compared to 1.6% for the placebo group.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44536083/palatin-technologies-touts-positive-results-from-mid-stage-study-for-experimental-drug-for-ulcerative-colitis-halts-patients-enrollment-citing-strategic-focus" rel="noreferrer noopener">Palatin Technologies Touts Positive Results From Mid-Stage Study For Experimental Drug For Ulcerative Colitis, Halts Patients Enrollment Citing Strategic Focus</a>
The primary analysis for additive effect demonstrated that:
<ul>
<li>40% of patients in the co-administered group achieved a 5% reduction in their body weight, compared to 27% for the tirzepatide alone group.</li>
<li>27% of patients in the co-administered group achieved a 6% reduction in their body weight, compared to 13% for the tirzepatide alone group.</li>
<li>19% of patients in the co-administered group achieved a 7% reduction in their body weight, compared to 0% for the tirzepatide alone group.</li>
</ul>
Over 50% of the lost weight was regained within two weeks after treatment cessation in both the co-administration and the tirzepatide-only groups, a common occurrence following the discontinuation of&nbsp;GLP-1/GIP therapy.
The data indicated that weight regain was effectively halted in the MC4R agonist bremelanotide group.
Additionally, co-administration of the MC4R agonist with the&nbsp;GLP-1/GIP therapy showed no increase in safety or tolerability concerns among patients.
Further data analysis is ongoing, including exploratory endpoints such as body composition and body mass index.
Palatin is advancing the development of its next-generation MC4R long-acting peptide and oral small molecule compounds as stand-alone treatments, as well as in combination with&nbsp;GLP-1/GIP (incretin therapy), and as monotherapy for multiple genetic obesity disorders.
Investigational New Drug applications are expected to be submitted in the fourth quarter of calendar 2025, with clinical data expected in the first half of 2026.
Price Action: PTN stock is down 14.6% at $0.5656 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/emerging-markets/25/03/44563420/despite-us-expansion-taiwan-semiconductor-reaffirms-commitment-to-home-base-with-new-initiatives-reuters" target="_blank" rel="noreferrer noopener">Despite US Expansion, Taiwan Semiconductor Reaffirms Commitment To Home Base With New Initiatives: Reuters</a></li>
</ul>
Photo via Shutterstock.

Biotech

Equities

Health Care

Palatin Technologies' Obesity Drug Co-Administered With Eli Lilly's Blockbuster Drug Shows 4.4% Reduction In Weight

The Company reported topline data with co-administered melanocortin-4 receptor (MC4R) agonist bremelanotide plus glucagon like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) tirzepatide and highlighted next steps in its obesity program for its novel next-generation MC4R long-acting peptides and oral small molecules.

Palatin Technologies Says BMT-801 Phase 2 Obesity Co-administration Study Met Its Primary Endpoint And Was Highly Statistically Significant

Palatin Technologies Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PTN#NYSE">PTN</a>) on Friday released topline results from its Phase 2 study of PL8177, a selective melanocortin-1 receptor (MC1R) agonist, in patients with <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">active ulcerative colitis</a>.
The Phase 2 randomized, placebo-controlled study evaluated 12 patients (nine in the PL8177 arm and three in the placebo arm) with active ulcerative colitis for <a href="https://www.benzinga.com/pressreleases/25/03/n44533405/palatin-announces-positive-topline-results-from-phase-2-ulcerative-colitis-uc-study-of-oral-melano" target="_blank" rel="noreferrer noopener">eight weeks of treatment</a>:
<ul>
<li>The company said clinical remission was achieved in 33% (3 of 9) of PL8177-treated patients versus 0% (0 of 3) on placebo.</li>
<li>Clinical response (statistically significant) was demonstrated in 78% (7 of 9) of PL8177-treated patients versus 33% (1 of 3) on placebo.</li>
<li>Symptomatic remission was achieved in 56% (5 of 9) of PL8177-treated patients versus 33% (1 of 3) on placebo.</li>
<li>Results for a subset of patients with more moderate disease at baseline showed that three of five (60%) PL8177-treated patients showed improvement in all three segments.
<ul>
<li>Four of five (80%) PL8177-treated patients showed improvement in two of the three segments.</li>
<li>Zero of one (0%) placebo patients showed improvement in two or more segments.</li>
</ul>
</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/cryptocurrency/25/03/44534582/galaxy-digital-to-pay-200-million-in-terra-luna-settlement-with-new-york-attorney-general" rel="noreferrer noopener">Galaxy Digital To Pay $200 Million In Terra-LUNA Settlement With New York Attorney General</a>
Treatment with oral PL8177 was well tolerated, and no treatment-related side effects were reported.
The study originally planned to enroll up to 28 patients, with an interim analysis after 12-16 participants. Due to a shift in strategic focus, Palatin stopped enrollment at 12 patients to accelerate out-licensing discussions and redirect resources to developing its melanocortin obesity assets.
As a result of lower patient numbers, the study was not powered to show statistical significance.
On Tuesday, the U.S. Food &amp; Drug Administration granted orphan drug designation to Palatin Technologies&#8217; PL7737, an oral treatment that activates the melanocortin-4 receptor, for leptin receptor deficiency, including obesity <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44470950/palatins-oral-mc4r-agonist-pl7737-receives-fda-orphan-drug-designation-for-obesity-due-to-leptin-r" rel="noreferrer noopener">caused by this condition</a>.
Price Action: PTN stock is down 2.43% at $0.68 during the premarket session at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44523147/candel-therapeutics-reports-prolonged-survival-in-mid-stage-study-for-pretreated-lung-cancer-patients" target="_blank" rel="noreferrer noopener">Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients</a></li>
</ul>
Image via Shutterstock

Palatin Technologies Touts Positive Results From Mid-Stage Study For Experimental Drug For Ulcerative Colitis, Halts Patients Enrollment Citing Strategic Focus

<ul>
<li>Clinical Remission: Achieved in 33% of PL8177-treated patients versus 0% on placebo after eight weeks of treatment.</li>
<li>Clinical Response (statistically significant): Demonstrated in 78% of PL8177-treated patients versus 33% on placebo after eight weeks of treatment (p&lt;0.005).</li>
</ul>

Palatin Reports Topline Results From Phase 2 Study Of PL8177; Says Endpoints Align With FDA's Recommended Primary And Key Secondary Endpoints For Evaluating Efficacy In UC Clinical Trials

<h3>Gainers</h3>
<ul>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) stock increased by 367.2% to $4.57 during Tuesday's pre-market session. The market value of their outstanding shares is at $14.3 million. The company's, Q4 earnings came out 3 days ago. </li>
<li>Predictive Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) shares rose 104.48% to $2.28. The company's market cap stands at $16.4 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) shares increased by 17.04% to $0.88. The company's market cap stands at $22.9 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) stock increased by 16.29% to $4.39. The company's market cap stands at $238.8 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) stock increased by 14.28% to $1.2. The company's market cap stands at $3.3 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares increased by 10.34% to $0.54. The company's market cap stands at $12.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Mural Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MURA#NASDAQ">MURA</a>) stock declined by 49.6% to $1.93 during Tuesday's pre-market session. The market value of their outstanding shares is at $33.2 million. </li>
<li>Orchestra BioMed Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>) shares declined by 17.95% to $3.75. The market value of their outstanding shares is at $141.8 million. </li>
<li>Cyclo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTH#NASDAQ">CYTH</a>) stock decreased by 12.77% to $0.62. The company's market cap stands at $20.2 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock declined by 10.52% to $0.24. The market value of their outstanding shares is at $3.1 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares decreased by 10.39% to $1.64. The market value of their outstanding shares is at $2.4 million. </li>
<li>Capstone Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPS#NASDAQ">CAPS</a>) stock declined by 9.75% to $2.5. The company's market cap stands at $3.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALMS

BSGM

CAPS

CYTH

GCTK

MURA

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

POAI

TNON

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

The FDA Has Granted Orphan Drug Designation To Palatin Technologies' PL7737, An Oral Treatment That Activates The Melanocortin-4 Receptor, For Leptin Receptor Deficiency, Including Obesity Caused By This Condition

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) with a Buy and lowers the price target from $17 to $7.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on Palatin Techs, Lowers Price Target to $7

Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.42) by 71.43 percent. This is a 78.57 percent increase over losses of $(0.56) per share from the same period last year.

Earnings

Earnings Beats

Palatin Techs Q2 2025 GAAP EPS $(0.12) Beats $(0.42) Estimate. Cash And Equivalents Of $3.4M

ABNB

AENT

AGIO

ALNY

AMAT

APDN

ATUS

AVNT

BENF

BFAM

BLIN

BPMC

BRKR

BTOC

CBRE

CEVA

CLBT

CNVS

COHU

COIN

CROX

CYBR

DDOG

DKNG

DNOW

DXCM

EEFT

EGAN

ELME

ELVA

FBRT

FROG

GDDY

GEHC

GPMT

Hannon Armstrong Sustainable Infrastructure Capital

HASI

HIMX

HOUS

HTGC

IMPP

INFA

IRDM

IRMD

ISSC

KELYA

KELYB

KNSL

LECO

LGCY

LPTH

NTWK

NVMI

Earnings Scheduled For February 13, 2025

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) with a Buy and maintains $17 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $17 Price Target

Press Releases

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Palatin Technologies' Obesity Drug Receives FDA Orphan Designation; Phase 2 Results Imminent (NYSE: PTN)

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Palatin Technologies' UC Treatment Shows Remarkable 78% Clinical Response Rate in Phase 2 Topline Data – Potential Game-Changer for Millions Suffering from Ulcerative Colitis (NYSE: PTN)

Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting

Palatin Technologies Scores Triple Win with Breakthrough Results in Obesity, Colitis, and Kidney Disease

Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal

Palatin Appeals NYSE American Notice of Delisting

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Alzamend Neuro

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Gr

Azitra

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Comments

Palatin Techs

Palatin Techs (PTN) オプション

Palatin Techs (AMEX:PTN) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル